Two experimental drug molecules promoted myelin repair in MS disease models, pointing toward a possible future route for treating nerve damage rather than only suppressing inflammation.
Nearly 80% of U.S. neurologists prescribing drugs for multiple sclerosis (MS) have received at least one pharma industry payment, with higher-volume prescribers more likely to be beneficiaries, finds ...
Tiziana Life Sciences (TLSA) stock is in focus as the company posts new data from an intranasal version of lead asset ...
Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...
ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was submitting its experimental multiple sclerosis drug fenebrutinib to global regulators after meeting late-stage trial goals ...
Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Swiss pharma giant Roche won approval from the ...
Jan 22 (Reuters) - The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of some multiple sclerosis drugs including Teva's (TEVA ...
BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...
Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results